Treatment Efficacy/Safety and Prognostic Factors in Patients with Advanced Biliary Tract Cancer Receiving Gemcitabine Monotherapy: An Analysis of 100 Cases

Publisher： Karger

E-ISSN： 1423-0232|79|1-2|39-45

ISSN： 0030-2414

Source： Oncology, Vol.79, Iss.1-2, 2010-11, pp. : 39-45

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and Safety of S-1 Monotherapy in Patients with Advanced Biliary Tract Adenocarcinoma

By  

Oncology, Vol. 76, Iss. 2, 2009-01 ,pp. : 126-132

Karger

Access to resources Recommend Favorite

S-1 Monotherapy in Patients with Advanced Biliary Tract Cancer

By  

Oncology, Vol. 77, Iss. 1, 2009-06 ,pp. : 71-74

Karger

Access to resources Recommend Favorite

Outcome of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (iFAM) Chemotherapy and Analysis of Prognostic Factors in Patients with Refractory Advanced Biliary Tract Cancer

By  

Oncology, Vol. 83, Iss. 2, 2012-06 ,pp. : 57-66

Karger

Access to resources Recommend Favorite

Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 8, 2018-04 ,pp. : 1671-1675

John Wiley & Sons Inc

Access to resources Recommend Favorite

Renal Toxicity Associated with Weekly Cisplatin and Gemcitabine Combination Therapy for Treatment of Advanced Biliary Tract Cancer

By  

Oncology, Vol. 87, Iss. 1, 2014-06 ,pp. : 30-39

Karger

Access to resources Recommend Favorite